Warning! GuruFocus detected
8 Severe warning signs
with STX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Shield Therapeutics PLC
ISIN : GB00BYV81293
Compare
Compare
Traded in other countries / regions
STX.UK1JS.GermanySHIEF.USA IPO Date
2016-02-26Description
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.41 | |||||
| Equity-to-Asset | 0.01 | |||||
| Debt-to-Equity | 36.94 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -7.42 | |||||
| Beneish M-Score | -0.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -45.6 | |||||
| 3-Year EPS without NRI Growth Rate | -26 | |||||
| 3-Year FCF Growth Rate | -54.2 | |||||
| 3-Year Book Growth Rate | -61.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -100.45 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 83.99 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.81 | |||||
| 9-Day RSI | 41.78 | |||||
| 14-Day RSI | 43.83 | |||||
| 3-1 Month Momentum % | 22.22 | |||||
| 6-1 Month Momentum % | -31.25 | |||||
| 12-1 Month Momentum % | 65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 0.9 | |||||
| Cash Ratio | 0.31 | |||||
| Days Inventory | 88.65 | |||||
| Days Sales Outstanding | 196.61 | |||||
| Days Payable | 124.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -86.2 | |||||
| Shareholder Yield % | -50.53 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.42 | |||||
| Operating Margin % | -157.74 | |||||
| Net Margin % | -168.54 | |||||
| FCF Margin % | -107.82 | |||||
| ROE % | -253.3 | |||||
| ROA % | -78.97 | |||||
| ROIC % | -110.97 | |||||
| 3-Year ROIIC % | 436.26 | |||||
| ROC (Joel Greenblatt) % | -1207.57 | |||||
| ROCE % | -115.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.43 | |||||
| PB Ratio | 31.58 | |||||
| EV-to-EBIT | -1.51 | |||||
| EV-to-Forward-EBIT | -4.2 | |||||
| EV-to-EBITDA | -1.57 | |||||
| EV-to-Forward-EBITDA | -5.73 | |||||
| EV-to-Revenue | 2.4 | |||||
| EV-to-Forward-Revenue | 0.93 | |||||
| EV-to-FCF | -2.22 | |||||
| Price-to-GF-Value | 0.5 | |||||
| Earnings Yield (Greenblatt) % | -66.14 | |||||
| FCF Yield % | -58.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shield Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ÂŁ) | 16.916 | ||
| EPS (TTM) (ÂŁ) | -0.04 | ||
| Beta | 2.35 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 101.73 | ||
| 14-Day RSI | 43.83 | ||
| 14-Day ATR (ÂŁ) | 0.002357 | ||
| 20-Day SMA (ÂŁ) | 0.031565 | ||
| 12-1 Month Momentum % | 65 | ||
| 52-Week Range (ÂŁ) | 0.01063 - 0.0587 | ||
| Shares Outstanding (Mil) | 1,041.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shield Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shield Therapeutics PLC Stock Events
| Event | Date | Price (ÂŁ) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shield Therapeutics PLC Frequently Asked Questions
What is Shield Therapeutics PLC(LSE:STX)'s stock price today?
The current price of LSE:STX is ÂŁ0.03. The 52 week high of LSE:STX is ÂŁ0.06 and 52 week low is ÂŁ0.01.
When is next earnings date of Shield Therapeutics PLC(LSE:STX)?
The next earnings date of Shield Therapeutics PLC(LSE:STX) is 2025-04-30 Est..
Does Shield Therapeutics PLC(LSE:STX) pay dividends? If so, how much?
Shield Therapeutics PLC(LSE:STX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers